The FDA has accepted the new drug application (NDA) of the synthetic, targeted radiotherapeutic agent 177 Lu-edotreotide (ITM ...
Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...
The FDA has granted 501 (k) clearance to the EXENT® System, a fully automated device for assessing monoclonal gammopathies, ...
FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the TCF family of ...
At the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, Meara explored the ...
What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...
Long-term follow-up of the international, multicenter phase 2 trial SAKK 01/10 found that single-dose carboplatin and involved-node radiotherapy (INRT) yielded an exceptional long-term performance ...
Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...
Frederick L. Locke, MD, chair in the department of blood and marrow transplant and cellular immunotherapy at Moffitt Cancer ...
International collaboration is crucial for enhancing rural cancer care, with shared experiences and solutions from across the ...
In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...
The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback